<SEC-DOCUMENT>0001950047-26-000250.txt : 20260107
<SEC-HEADER>0001950047-26-000250.hdr.sgml : 20260107
<ACCEPTANCE-DATETIME>20260107162709
ACCESSION NUMBER:		0001950047-26-000250
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260107
DATE AS OF CHANGE:		20260107

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apogee Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001974640
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				934958665
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-41740
		FILM NUMBER:		26516001

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 17, SUITE 102B
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		650-394-5230

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 17, SUITE 102B
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Apogee Therapeutics, LLC
		DATE OF NAME CHANGE:	20230420

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dambkowski Carl
		CENTRAL INDEX KEY:			0001983476
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 17, SUITE 102B
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:ns2="http://www.sec.gov/edgar/common">
    <headerData>
        <submissionType>144</submissionType>
        <filerInfo>
            <filer>
                <filerCredentials>
                    <cik>0001983476</cik>
                    <ccc>XXXXXXXX</ccc>
                </filerCredentials>
            </filer>
            <liveTestFlag>LIVE</liveTestFlag>



        </filerInfo>
    </headerData>
    <formData>
        <issuerInfo>
            <issuerCik>0001974640</issuerCik>
            <issuerName>APOGEE THERAPEUTICS INC</issuerName>
            <secFileNumber>001-41740</secFileNumber>
            <issuerAddress>
                <ns2:street1>221 Crescent St., Building 17</ns2:street1>
                <ns2:city>Waltham</ns2:city>
                <ns2:stateOrCountry>MA</ns2:stateOrCountry>
                <ns2:zipCode>02453</ns2:zipCode>
            </issuerAddress>
            <issuerContactPhone>6503945230</issuerContactPhone>
            <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>CARL DAMBKOWSKI</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
            <relationshipsToIssuer>
                <relationshipToIssuer>Officer</relationshipToIssuer>
            </relationshipsToIssuer>
        </issuerInfo>
        <securitiesInformation>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <brokerOrMarketmakerDetails>
                <name>Morgan Stanley Smith Barney LLC Executive Financial Services</name>
                <address>
                    <ns2:street1>1 New York Plaza</ns2:street1>
                    <ns2:street2>8th Floor</ns2:street2>
                    <ns2:city>New York</ns2:city>
                    <ns2:stateOrCountry>NY</ns2:stateOrCountry>
                    <ns2:zipCode>10004</ns2:zipCode>
                </address>
            </brokerOrMarketmakerDetails>
            <noOfUnitsSold>35200</noOfUnitsSold>
            <aggregateMarketValue>2754400.00</aggregateMarketValue>
            <noOfUnitsOutstanding>68320229</noOfUnitsOutstanding>
            <approxSaleDate>01/07/2026</approxSaleDate>
            <securitiesExchangeName>NASDAQ</securitiesExchangeName>
        </securitiesInformation>
        <securitiesToBeSold>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <acquiredDate>01/07/2026</acquiredDate>
            <natureOfAcquisitionTransaction>Exercise of Stock Options</natureOfAcquisitionTransaction>
            <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
            <isGiftTransaction>N</isGiftTransaction>
            <amountOfSecuritiesAcquired>26400</amountOfSecuritiesAcquired>
            <paymentDate>01/07/2026</paymentDate>
            <natureOfPayment>Cash</natureOfPayment>
        </securitiesToBeSold>
        <securitiesToBeSold>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <acquiredDate>09/16/2022</acquiredDate>
            <natureOfAcquisitionTransaction>Restricted Stock Awards</natureOfAcquisitionTransaction>
            <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
            <isGiftTransaction>N</isGiftTransaction>
            <amountOfSecuritiesAcquired>8800</amountOfSecuritiesAcquired>
            <paymentDate>09/16/2022</paymentDate>
            <natureOfPayment>N/A</natureOfPayment>
        </securitiesToBeSold>
        <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
        <securitiesSoldInPast3Months>
            <sellerDetails>
                <name>10b5-1 Sales for CARL DAMBKOWSKI</name>
                <address>
                    <ns2:street1>221 Crescent St., Building 17</ns2:street1>
                    <ns2:city>Waltham</ns2:city>
                    <ns2:stateOrCountry>MA</ns2:stateOrCountry>
                    <ns2:zipCode>02453</ns2:zipCode>
                </address>
            </sellerDetails>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <saleDate>12/04/2025</saleDate>
            <amountOfSecuritiesSold>10900</amountOfSecuritiesSold>
            <grossProceeds>817528.34</grossProceeds>
        </securitiesSoldInPast3Months>
        <securitiesSoldInPast3Months>
            <sellerDetails>
                <name>10b5-1 Sales for CARL DAMBKOWSKI</name>
                <address>
                    <ns2:street1>221 Crescent St., Building 17</ns2:street1>
                    <ns2:city>Waltham</ns2:city>
                    <ns2:stateOrCountry>MA</ns2:stateOrCountry>
                    <ns2:zipCode>02453</ns2:zipCode>
                </address>
            </sellerDetails>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <saleDate>11/05/2025</saleDate>
            <amountOfSecuritiesSold>8060</amountOfSecuritiesSold>
            <grossProceeds>443860.98</grossProceeds>
        </securitiesSoldInPast3Months>
        <securitiesSoldInPast3Months>
            <sellerDetails>
                <name>10b5-1 Sales for CARL DAMBKOWSKI</name>
                <address>
                    <ns2:street1>221 Crescent St., Building 17</ns2:street1>
                    <ns2:city>Waltham</ns2:city>
                    <ns2:stateOrCountry>MA</ns2:stateOrCountry>
                    <ns2:zipCode>02453</ns2:zipCode>
                </address>
            </sellerDetails>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <saleDate>11/05/2025</saleDate>
            <amountOfSecuritiesSold>2725</amountOfSecuritiesSold>
            <grossProceeds>150064.66</grossProceeds>
        </securitiesSoldInPast3Months>
        <remarks>The 26,400 securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
The 8,800 securities to be sold were acquired upon the vesting of restricted stock units on 09/16/2022 and 12/14/2022.
</remarks>
        <noticeSignature>
            <noticeDate>01/07/2026</noticeDate>
            <planAdoptionDates>
                <planAdoptionDate>09/22/2025</planAdoptionDate>
            </planAdoptionDates>
            <signature>/s/ Carl Dambkowski</signature>
        </noticeSignature>
    </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
